Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 102, Issue 1, Pages 20-35Publisher
WILEY
DOI: 10.1111/ejh.13172
Keywords
acute myeloid leukemia; molecular markers; prognostic impact
Categories
Funding
- Olympia-Morata program from the Medical Faculty of the Heidelberg University
- NCI (NCI Leukemia SPORE) [P50 CA100632]
Ask authors/readers for more resources
The recently updated World Health Organization (WHO) Classification of myeloid neoplasms and leukemia reflects the fact that research in the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has led to remarkable advances in our understanding of the disease. Gene mutations now allow us to explore the enormous diversity among cytogenetically defined subsets of AML, particularly the large subset of cytogenetically normal AML. Despite the progress in unraveling the tumor genome, only a small number of recurrent mutations have been incorporated into risk-stratification schemes and have been proven to be clinically relevant, targetable lesions. We here discuss the utility of molecular markers in AML in prognostication and treatment decision making, specifically highlighting the aberrations included in the current WHO classification.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available